Impact of SGLT2 inhibitors on the risk of age‐related ocular diseases in patients with type 2 diabetes mellitus: A target trial emulation study
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Yueh-Tsung Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Macular Degeneration, Eye Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Chronic ocular diseases such as age‐related macular degeneration (AMD) are leading causes of vision loss in older adults. While sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) are widely prescribed in the management of type 2 diabetes mellitus (T2DM), their effects on ocular disease risk remain largely unknown. Materials and Methods This retrospective cohort study evaluated the association between SGLT2i use and the risk of AMD and other age‐related ocular conditions in adults aged ≥60 with T2DM, using a target trial emulation framework based on the TriNetX global health research network (2013–2025). Patients initiating SGLT2i or dipeptidyl peptidase‐4 inhibitors (DPP4i) were propensity‐matched 1:1. Primary outcomes were incident non‐exudative, exudative, and atrophic AMD, and secondary outcomes included cataract, ocular hypertension, and primary open‐angle glaucoma.
Results
In 12 156 matched patients, SGLT2i use was associated with significantly lower risks of non‐exudative AMD (HR 0.64; 95% CI 0.49–0.84) and exudative AMD (HR 0.56; 95% CI 0.33–0.96) compared with DPP4i use. A slight increase in the risk of cataract was observed (HR 1.08; 95% CI 1.02–1.15), while no significant differences were found for atrophic AMD, ocular hypertension, or glaucoma.
Conclusions
These findings suggest that SGLT2i may offer retinal protective effects in older adults with T2DM, supporting further mechanistic and prospective clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- Department of Surgery, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan.
- Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Pharmacy, Yuanlin Christian Hospital, Changhua, Taiwan.
- Department of Pharmacy, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan.
ORCID-Profile: Jheng-Yan Wu, Tsung W Chang
Zitieren
APA
Lee, Y. T., Wu, J. Y., Chang, T. W., & Hung, C. H. (2025). Impact of SGLT2 inhibitors on the risk of age‐related ocular diseases in patients with type 2 diabetes mellitus: A target trial emulation study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70131
Vancouver
Lee YT, Wu JY, Chang TW, Hung CH. Impact of SGLT2 inhibitors on the risk of age‐related ocular diseases in patients with type 2 diabetes mellitus: A target trial emulation study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70131
BibTeX
@article{Lee2025,
author = {Lee, Yueh-Tsung and Wu, Jheng-Yan and Chang, Tsung W and Hung, Cheng-Hsien},
title = {Impact of SGLT2 inhibitors on the risk of age‐related ocular diseases in patients with type 2 diabetes mellitus: A target trial emulation study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70131}
}
EUVIMED